Literature DB >> 15118831

Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells.

Ingrid Hilger1, Yvonne Leistner, Alexander Berndt, Christine Fritsche, Karl Michael Haas, Hartwig Kosmehl, Werner A Kaiser.   

Abstract

The aim of this study was to evaluate in vitro and in vivo imaging of HER-2-over-expressing tumours using near-infrared optical imaging. A fluorochrome probe was designed by coupling Cy5.5 to anti-HER-2 antibodies. Cells over-expressing (SK-BR-3 cells) or normally expressing (PE/CA-PJ34 cells) the HER-2 protein were incubated with the probe. After removing unbound probe molecules, fluorescence intensities were determined (a.u.: arbitrary units). Cells were additionally investigated using FACS and laser scanning microscopy. The probe was also injected intravenously into tumours bearing SK-BR-3 ( n=3) or PE/CA-PJ34 ( n=3). Whole-body fluorescence images were generated and analysed. The incubation of SK-BR-3 cells with the probe led to higher fluorescence intensities [2,133 (+/-143) a.u.] compared to controls [975 (+/-95) a.u.]. The results from FACS and immunocytochemical analysis were in agreement with these findings. A distinct dependency between the fluorescence intensity and the cell number used in the incubations was detected. In vivo, the relative fluorescence intensities in SK-BR-3 tumours were higher than in PE/CA-PJ34 tumours at 16-24 h after probe application. HER-2-over-expressing tumours were depictable in their original size. Labelling of HER-2 with Cy5.5 is suitable for in vitro and in vivo detection of HER-2-over-expressing tumour cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118831     DOI: 10.1007/s00330-004-2257-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  21 in total

1.  Three-dimensional time-resolved optical tomography of a conical breast phantom.

Authors:  J C Hebden; H Veenstra; H Dehghani; E M Hillman; M Schweiger; S R Arridge; D T Delpy
Journal:  Appl Opt       Date:  2001-07-01       Impact factor: 1.980

2.  Fluorescence molecular tomography resolves protease activity in vivo.

Authors:  Vasilis Ntziachristos; Ching-Hsuan Tung; Christoph Bremer; Ralph Weissleder
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

Review 3.  Shedding light onto live molecular targets.

Authors:  Ralph Weissleder; Vasilis Ntziachristos
Journal:  Nat Med       Date:  2003-01       Impact factor: 53.440

Review 4.  Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

Authors:  Kate McKeage; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

Authors:  S Shak
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

6.  Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256).

Authors:  Hisataka Kobayashi; Kazuo Shirakawa; Satomi Kawamoto; Tsuneo Saga; Noriko Sato; Akira Hiraga; Ichiro Watanabe; Yuji Heike; Kaori Togashi; Junji Konishi; Martin W Brechbiel; Hiro Wakasugi
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

Authors:  R Seshadri; F A Firgaira; D J Horsfall; K McCaul; V Setlur; P Kitchen
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

9.  Oral squamous cell carcinoma invasion is associated with a laminin-5 matrix re-organization but independent of basement membrane and hemidesmosome formation. clues from an in vitro invasion model.

Authors:  A Berndt; P Hyckel; A Könneker; D Katenkamp; H Kosmehl
Journal:  Invasion Metastasis       Date:  1997

Review 10.  The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.

Authors:  P M Ravdin; G C Chamness
Journal:  Gene       Date:  1995-06-14       Impact factor: 3.688

View more
  25 in total

1.  [Functional and molecular imaging of breast tumors].

Authors:  K Pinker; P Brader; G Karanikas; K El-Rabadi; W Bogner; S Gruber; M Reisegger; S Trattnig; T H Helbich
Journal:  Radiologe       Date:  2010-11       Impact factor: 0.635

2.  Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors.

Authors:  Susan P Foy; Rachel L Manthe; Steven T Foy; Sanja Dimitrijevic; Nishanth Krishnamurthy; Vinod Labhasetwar
Journal:  ACS Nano       Date:  2010-09-28       Impact factor: 15.881

3.  Molecular fluorescence, phosphorescence, and chemiluminescence spectrometry.

Authors:  Kristin A Fletcher; Sayo O Fakayode; Mark Lowry; Sheryl A Tucker; Sharon L Neal; Irene W Kimaru; Matthew E McCarroll; Gabor Patonay; Philip B Oldham; Oleksandr Rusin; Robert M Strongin; Isiah M Warner
Journal:  Anal Chem       Date:  2006-06-15       Impact factor: 6.986

Review 4.  Fluorescent molecular imaging: technical progress and current preclinical and clinical applications in urogynecologic diseases.

Authors:  V M Alexander; P L Choyke; H Kobayashi
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 5.  Antibody-based imaging of HER-2: moving into the clinic.

Authors:  R E Wang; Y Zhang; L Tian; W Cai; J Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 6.  Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics.

Authors:  Anne Hellebust; Rebecca Richards-Kortum
Journal:  Nanomedicine (Lond)       Date:  2012-03       Impact factor: 5.307

7.  Novel fluorophores as building blocks for optical probes for in vivo near infrared fluorescence (NIRF) imaging.

Authors:  Jutta Pauli; Robert Brehm; Monika Spieles; Werner A Kaiser; Ingrid Hilger; Ute Resch-Genger
Journal:  J Fluoresc       Date:  2010-03-06       Impact factor: 2.217

8.  A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor.

Authors:  Zheng Miao; Gang Ren; Lei Jiang; Hongguang Liu; Jack M Webster; Rong Zhang; Mohammad Namavari; Sanjiv S Gambhir; Faisal Syud; Zhen Cheng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-15       Impact factor: 9.236

Review 9.  New strategies for fluorescent probe design in medical diagnostic imaging.

Authors:  Hisataka Kobayashi; Mikako Ogawa; Raphael Alford; Peter L Choyke; Yasuteru Urano
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

10.  A novel fluorescent imaging agent for diffuse optical tomography of the breast: first clinical experience in patients.

Authors:  Stephanie van de Ven; Andrea Wiethoff; Tim Nielsen; Bernhard Brendel; Marjolein van der Voort; Rami Nachabe; Martin Van der Mark; Michiel Van Beek; Leon Bakker; Lueder Fels; Sjoerd Elias; Peter Luijten; Willem Mali
Journal:  Mol Imaging Biol       Date:  2009-10-02       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.